IMMP – Immutep Limited ADR
IMMP — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.47
Margin Of Safety %
Put/Call OI Ratio
0.05
EPS Next Q Diff
EPS Last/This Y
-0.02
EPS This/Next Y
0.12
Price
0.39
Target Price
0.89
Analyst Recom
2.33
Performance Q
-10.78
Upside
-3,420.5%
Beta
2.21
Ticker: IMMP
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | IMMP | 0.4501 | 0.02 | 0.00 | 7145 |
| 2026-07-14 | IMMP | 0.4367 | 0.02 | 0.14 | 7305 |
| 2026-07-15 | IMMP | 0.4399 | 0.02 | 0.81 | 7336 |
| 2026-07-16 | IMMP | 0.4403 | 0.03 | 0.08 | 7365 |
| 2026-07-17 | IMMP | 0.4182 | 0.03 | 0.00 | 7506 |
| 2026-07-20 | IMMP | 0.41 | 0.03 | 0.06 | 3123 |
| 2026-07-21 | IMMP | 0.3999 | 0.03 | 0.47 | 3349 |
| 2026-07-22 | IMMP | 0.3891 | 0.03 | 3.67 | 3384 |
| 2026-07-23 | IMMP | 0.399 | 0.05 | 2.33 | 3444 |
| 2026-07-24 | IMMP | 0.3875 | 0.03 | 2.75 | 3384 |
| 2026-07-27 | IMMP | 0.3858 | 0.03 | 1.50 | 3390 |
| 2026-07-28 | IMMP | 0.381 | 0.04 | 0.00 | 3444 |
| 2026-07-29 | IMMP | 0.38 | 0.03 | 1.48 | 3413 |
| 2026-07-30 | IMMP | 0.3833 | 0.04 | 3.58 | 3458 |
| 2026-07-31 | IMMP | 0.3874 | 0.03 | 1.41 | 3439 |
| 2026-08-03 | IMMP | 0.3844 | 0.04 | 1.76 | 3448 |
| 2026-08-04 | IMMP | 0.395 | 0.05 | 0.04 | 3482 |
| 2026-08-05 | IMMP | 0.3846 | 0.04 | 0.31 | 3506 |
| 2026-08-07 | IMMP | 0.388 | 0.05 | 1.39 | 3566 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | IMMP | 0.45 | - | 59.6 | -0.32 |
| 2026-07-14 | IMMP | 0.44 | - | 59.8 | -0.32 |
| 2026-07-15 | IMMP | 0.44 | - | 59.8 | -0.32 |
| 2026-07-16 | IMMP | 0.44 | - | 59.6 | -0.32 |
| 2026-07-17 | IMMP | 0.42 | - | 59.7 | -0.32 |
| 2026-07-20 | IMMP | 0.41 | - | 60.2 | -0.32 |
| 2026-07-21 | IMMP | 0.40 | - | 60.3 | -0.32 |
| 2026-07-22 | IMMP | 0.39 | - | 60.5 | -0.32 |
| 2026-07-23 | IMMP | 0.39 | - | 60.6 | -0.32 |
| 2026-07-24 | IMMP | 0.39 | - | 60.6 | -0.32 |
| 2026-07-27 | IMMP | 0.38 | - | 60.6 | -0.32 |
| 2026-07-28 | IMMP | 0.38 | - | 60.7 | -0.32 |
| 2026-07-29 | IMMP | 0.38 | - | 60.7 | -0.32 |
| 2026-07-30 | IMMP | 0.39 | - | 60.5 | -0.32 |
| 2026-07-31 | IMMP | 0.39 | - | 60.5 | -0.32 |
| 2026-08-03 | IMMP | 0.38 | - | 60.8 | -0.32 |
| 2026-08-04 | IMMP | 0.38 | - | 60.8 | -0.32 |
| 2026-08-05 | IMMP | 0.38 | - | 60.8 | -0.32 |
| 2026-08-06 | IMMP | 0.37 | - | 60.8 | -0.32 |
| 2026-08-07 | IMMP | 0.39 | - | 61.3 | -0.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | IMMP | 0.00 | -58.78 | 2.67 |
| 2026-07-14 | IMMP | 0.00 | -58.78 | 2.67 |
| 2026-07-15 | IMMP | 0.00 | -58.78 | 2.67 |
| 2026-07-16 | IMMP | 0.00 | -58.78 | 2.67 |
| 2026-07-17 | IMMP | 0.00 | -58.78 | 2.67 |
| 2026-07-20 | IMMP | 0.00 | -58.62 | 2.67 |
| 2026-07-21 | IMMP | 0.00 | -58.62 | 2.67 |
| 2026-07-22 | IMMP | 0.00 | -58.62 | 2.67 |
| 2026-07-23 | IMMP | 0.00 | -58.62 | 2.67 |
| 2026-07-24 | IMMP | 0.00 | -58.62 | 2.67 |
| 2026-07-27 | IMMP | 0.00 | -58.06 | 1.47 |
| 2026-07-28 | IMMP | 0.00 | -58.06 | 1.47 |
| 2026-07-29 | IMMP | 0.00 | -58.06 | 1.47 |
| 2026-07-30 | IMMP | 0.00 | -58.06 | 1.47 |
| 2026-07-31 | IMMP | 0.00 | -58.06 | 1.47 |
| 2026-08-03 | IMMP | 0.00 | -58.86 | 1.47 |
| 2026-08-04 | IMMP | 0.00 | -58.86 | 1.47 |
| 2026-08-05 | IMMP | 0.00 | -58.86 | 1.47 |
| 2026-08-06 | IMMP | 0.00 | -58.86 | 1.47 |
| 2026-08-07 | IMMP | 0.00 | -58.86 | 1.47 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-58.86
Beta
2.21
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
25
Growth Score
18
Sentiment Score
20
Actual DrawDown %
92.2
Max Drawdown 5-Year %
-93.6
Target Price
0.89
P/E
Forward P/E
PEG
P/S
21.29
P/B
0.86
P/Free Cash Flow
EPS
-0.37
Average EPS Est. Cur. Y
-0.32
EPS Next Y. (Est.)
-0.2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2026.12
Relative Volume
0.11
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-96.1
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.07
EBIT Estimation
61.3
◆
IMMP
Healthcare
$0.39
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
44.6
Range 1M
23.5%
Sup Dist
8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
11.8%
EPS NY
55%
52W%
2.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+128.2% upside
Upside
+128.2%
Quality
25
IMMP — P/E HistoricalBiotechnology
Immutep LimitedSector: Healthcare
Industry: Biotechnology
Employees:
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
IMMP
Latest News
—
Caricamento notizie per IMMP…
stock quote shares IMMP – Immutep Limited ADR Stock Price stock today
news today IMMP – Immutep Limited ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMMP – Immutep Limited ADR yahoo finance google finance
stock history IMMP – Immutep Limited ADR invest stock market
stock prices IMMP premarket after hours
ticker IMMP fair value insiders trading